These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8205294)

  • 1. Hypertension as a risk factor for progression of chronic renal disease.
    Epstein M
    Blood Press Suppl; 1994; 1():23-8. PubMed ID: 8205294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of ACE inhibitors and calcium antagonists on progression of chronic renal disease.
    Epstein M
    Blood Press Suppl; 1995; 2():108-12. PubMed ID: 7582066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. National High Blood Pressure Education Program Working Group report on hypertension and chronic renal failure.
    Arch Intern Med; 1991 Jul; 151(7):1280-7. PubMed ID: 2064478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Are all antihypertensive drugs renoprotective?].
    Wolf S; Risler T
    Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Retrospective studies and prospects of therapy for hypertension].
    Maisch B; Brilla C; Kruse T; Noll B; Bethge C
    Herz; 1995 Dec; 20(6):370-89. PubMed ID: 8582697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of hypertension in chronic kidney disease.
    Toto RD
    Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How much must blood pressure be reduced in order to obtain the remission of chronic renal disease?
    Pisoni R; Remuzzi G
    J Nephrol; 2000; 13(3):228-31. PubMed ID: 10928301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.
    Suzuki H; Kanno Y; Nakamoto H; Okada H; Sugahara S
    Clin Exp Hypertens; 2005; 27(2-3):129-38. PubMed ID: 15835375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The future of antihypertensive treatment.
    Israili ZH; Hernández-Hernández R; Valasco M
    Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
    Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
    Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term renal function in primary hypertension. An epidemiological and pathophysiological study.
    Siewert-Delle A
    Scand J Urol Nephrol Suppl; 1999; 199():1-36. PubMed ID: 10349677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcium antagonists and renal protection: emerging perspectives.
    Epstein M
    J Hypertens Suppl; 1998 Sep; 16(4):S17-25. PubMed ID: 9817188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hypertension and renal disease].
    Kamper AL; Pedersen EB; Strandgaard S
    Ugeskr Laeger; 2009 Jun; 171(25):2109-13. PubMed ID: 19671393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-converting enzyme inhibition and renal protection. An assessment of implications for therapy.
    Hollenberg NK; Raij L
    Arch Intern Med; 1993 Nov; 153(21):2426-35. PubMed ID: 8215747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy.
    Khan NA; McAlister FA; Lewanczuk RZ; Touyz RM; Padwal R; Rabkin SW; Leiter LA; Lebel M; Herbert C; Schiffrin EL; Herman RJ; Hamet P; Fodor G; Carruthers G; Culleton B; DeChamplain J; Pylypchuk G; Logan AG; Gledhill N; Petrella R; Campbell NR; Arnold M; Moe G; Hill MD; Jones C; Larochelle P; Ogilvie RI; Tobe S; Houlden R; Burgess E; Feldman RD;
    Can J Cardiol; 2005 Jun; 21(8):657-72. PubMed ID: 16003449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which antihypertensive drugs are the most nephroprotective and why?
    Cravedi P; Ruggenenti P; Remuzzi G
    Expert Opin Pharmacother; 2010 Nov; 11(16):2651-63. PubMed ID: 20977400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertension in children with chronic renal failure.
    Lilova M
    Turk J Pediatr; 2005; 47 Suppl():28-31. PubMed ID: 15884664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.